These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17563732)

  • 61. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
    Dodero A; Perfetti V; Ciceri F; Corradini P
    Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
    [No Abstract]   [Full Text] [Related]  

  • 63. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
    Ringhoffer M; Harsdorf Sv; Schmitt M; Wiesneth M; Zenz T; Stilgenbauer S; Greiner J; Döhner K; Marx M; Döhner H; Bunjes D
    Br J Haematol; 2007 Jan; 136(1):127-30. PubMed ID: 17222200
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.
    Ballester OF; Fang T; Raptis A; Ballester G; Wilcox P; Hiemenz J; Tan B
    Bone Marrow Transplant; 2004 Sep; 34(5):419-23. PubMed ID: 15286696
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
    Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Vaessen N; Claas EC; Barge RM; Kroes AC
    Bone Marrow Transplant; 2007 Jul; 40(2):137-43. PubMed ID: 17530007
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
    Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
    Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
    Uy GL; Goyal SD; Fisher NM; Oza AY; Tomasson MH; Stockerl-Goldstein K; DiPersio JF; Vij R
    Bone Marrow Transplant; 2009 May; 43(10):793-800. PubMed ID: 19029964
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
    Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
    Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
    Kröger N
    Leukemia; 2007 Sep; 21(9):1851-8. PubMed ID: 17568819
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
    Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
    Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival.
    Norlin AC; Sairafi D; Mattsson J; Ljungman P; Ringdén O; Remberger M
    Bone Marrow Transplant; 2008 Feb; 41(3):267-73. PubMed ID: 17994123
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Allogeneic transplantation in lymphoma: current status.
    Schmitz N; Dreger P; Glass B; Sureda A
    Haematologica; 2007 Nov; 92(11):1533-48. PubMed ID: 18024402
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT.
    Ting DT; Spitzer TR; Chaudhary A; Muzikansky A; Colby C; Power K; McAfee S; Ballen K; Attar E; Saidman SL; Preffer F; Sykes M; Dey BR
    Bone Marrow Transplant; 2008 Sep; 42(5):329-35. PubMed ID: 18587439
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.
    Bregni M; Bernardi M; Servida P; Pescarollo A; Crocchiolo R; Treppiedi E; Corradini P; Ciceri F; Peccatori J
    Bone Marrow Transplant; 2009 Aug; 44(4):237-42. PubMed ID: 19234510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.